Abstract
Production of beta-lactamases is one of the most common mechanisms of bacterial resistance to beta-lactam antibiotics. In the clinical setting, the introduction of new classes of beta-lactams has invariably been followed by the emergence of new beta-lactamases capable of degrading them, as a paradigmatic example of rapid bacterial evolution under a rapidly changing selective environment. The scope of this article is to provide an overview on the recent evolution of beta-lactamase-mediated resistance among bacterial pathogens. Focus is on the mechanisms of evolution and dissemination of enzymes of greater clinical impact, including the extended-spectrum beta-lactamases, the AmpC-type beta-lactamases and the carbapenemases, which are currently responsible for emerging resistance to the most recent and powerful beta-lactams (the expanded-spectrum cephalosporins and the carbapenems) among major Gram-negative pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter.
| Original language | English |
|---|---|
| Pages (from-to) | 295-308 |
| Number of pages | 14 |
| Journal | Future Microbiology |
| Volume | 1 |
| DOIs | |
| Publication status | Published - Oct 2006 |
Fingerprint
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
Cite this
New beta-lactamases : a paradigm for the rapid response of bacterial evolution in the clinical setting. / Rossolini, Gian Maria; Docquier, Jean Denis.
In: Future Microbiology, Vol. 1, 10.2006, p. 295-308.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New beta-lactamases
T2 - a paradigm for the rapid response of bacterial evolution in the clinical setting.
AU - Rossolini, Gian Maria
AU - Docquier, Jean Denis
PY - 2006/10
Y1 - 2006/10
N2 - Production of beta-lactamases is one of the most common mechanisms of bacterial resistance to beta-lactam antibiotics. In the clinical setting, the introduction of new classes of beta-lactams has invariably been followed by the emergence of new beta-lactamases capable of degrading them, as a paradigmatic example of rapid bacterial evolution under a rapidly changing selective environment. The scope of this article is to provide an overview on the recent evolution of beta-lactamase-mediated resistance among bacterial pathogens. Focus is on the mechanisms of evolution and dissemination of enzymes of greater clinical impact, including the extended-spectrum beta-lactamases, the AmpC-type beta-lactamases and the carbapenemases, which are currently responsible for emerging resistance to the most recent and powerful beta-lactams (the expanded-spectrum cephalosporins and the carbapenems) among major Gram-negative pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter.
AB - Production of beta-lactamases is one of the most common mechanisms of bacterial resistance to beta-lactam antibiotics. In the clinical setting, the introduction of new classes of beta-lactams has invariably been followed by the emergence of new beta-lactamases capable of degrading them, as a paradigmatic example of rapid bacterial evolution under a rapidly changing selective environment. The scope of this article is to provide an overview on the recent evolution of beta-lactamase-mediated resistance among bacterial pathogens. Focus is on the mechanisms of evolution and dissemination of enzymes of greater clinical impact, including the extended-spectrum beta-lactamases, the AmpC-type beta-lactamases and the carbapenemases, which are currently responsible for emerging resistance to the most recent and powerful beta-lactams (the expanded-spectrum cephalosporins and the carbapenems) among major Gram-negative pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter.
UR - http://www.scopus.com/inward/record.url?scp=34547958256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547958256&partnerID=8YFLogxK
U2 - 10.2217/17460913.1.3.295
DO - 10.2217/17460913.1.3.295
M3 - Article
VL - 1
SP - 295
EP - 308
JO - Future Microbiology
JF - Future Microbiology
SN - 1746-0913
ER -